Botulinum toxin efficacy for the treatment of pain

Journal of Clinical Anesthesia

Volumn 17, Issue 5, 2005, Pages 328-330

  Acquadro, Martin A ^a,b   Borodic, Gary E ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; DULOXETINE;

CLINICAL TRIAL; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HEADACHE; HUMAN; MIGRAINE; MYOFASCIAL PAIN; NECK PAIN; NEUROPATHIC PAIN; NONHUMAN; PAIN; PRIORITY JOURNAL; SIDE EFFECT;

BOTULINUM TOXINS; FACIAL PAIN; HEADACHE; HUMANS;

EID: 23644452670     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinane.2005.02.006     Document Type: Editorial

References (27)

1. M.A. Acquadro, and G.E. Borodic Treatment of myofascial pain with botulinum A toxin Anesthesiology 80 1994 705 706
2. W.J. Binder, M.F. Brinn, A. Blitzer, L.D. Schoenrock, and J.M. Pogoda Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study Otolaryngol Head Neck Surg 123 2000 669 676
3. R.W. Evans, and A. Blumenfeld Botulinum toxin injections for headaches Headache 43 2003 682 685
4. J. Pascual Influence of botulinum toxin treatment on previous primary headaches in patients with cranio-cervical dystonia Neurologia 19 2004 260 263
5. A. Blumenfeld Botulinum toxin type A for the treatment of headache: pro Headache 44 2004 825 830
6. D.W. Dodick Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside Headache 43 Suppl 1 2003 525 533
7. E.J. Eross, J.P. Gladstone, S. Lewis, R. Rogers, and D.W. Dodick Duration of migraine is a predictor for response to botulinum toxin type A Headache 45 2005 308 314
8. N.T. Mathew, B.M. Frishberg, and M. Gawel botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial Headache 45 2005 293 307
9. D.W. Dodick, A. Mauskop, and A.H. Elkind Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study Headache 45 2005 315 324
10. H. Iida, K. Sumi, M. Takenaka, T. Asano, S. Matsumoto, T. Iwama, and S. Dohi Periorbital pain associated with hemifacial spasms that responded to botulinum toxin treatment and microvascular decompression surgey: a case report J Clin Anesth 17 2005 363 365
11. K.M. Welch Botulinum toxin type A for the treatment of headache: con Headache 44 2004 831 833
12. G.E. Borodic, L. Mills, and M. Joseph Botulinum A toxin for adult onset spasmodic torticollis Plast Reconstr Surg 87 1991 285 289
13. S. Evers, J. Vollmer-Haase, S. Schwaag, A. Rahman, I.-W. Husstedt, and A. Frese Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double blind, placebo-controlled study Cephalgia 24 2004 838 843
14. S. Silberstein, N. Mathew, J. Saper, and S. Jenkins Botulinum toxin A as a migraine preventive treatment Headache 40 2000 445 450
15. J.D. Rollnik, O. Tannenberger, M. Schubert, U. Schneider, and R. Dengler Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study Headache 40 2000 300 305
16. W.J. Schmitt, E. Slowey, N. Fravi, S. Weber, and J.-M. Burgunder Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial Headache 41 2001 658 664
17. M. Padberg, S.F. de Bruijn, R.J. de Haan, and D.L. Tavy Treatment of chronic tension-type headache with botulinum toxin: a double-blind placebo-controlled trial Cephalgia 24 2004 675 680
18. W.J. Schulte-Mattler, and P. Krack Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study Pain 109 2004 110 114
19. W.G. Ondo, K.D. Vuong, and H.S. Derman Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study Cephalgia 24 2004 60 65
20. C.J. Woolf Pain: moving from symptom control toward mechanism-specific pharmacologic management Ann Intern Med 140 2004 441 451
21. C.J. Woolf, and R.J. Mannion Neuropathic pain: aetiology, symptoms, mechanisms, and management Lancet 353 1999 1959 1964
22. C.J. Woolf, and M. Costigan Transcriptional and post-translational plasticity and the generation of inflammatory pain Proc Natl Acad Sci U S A 96 1999 7723 7730
23. P.L. Durham, R. Cady, and R. Cady Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells botulinum toxin A: implications for migraine therapy Headache 44 2004 35 41
24. L.R. Watkins, and S.F. Maier Beyond neurons: evidence that immune and glial cells contribute to pathologic pain states Physiol Rev 82 2002 981 1011
25. L.R. Watkins, E.D. Milligan, and S.F. Maier Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain Adv Exp Med Biol 521 2003 1 21
26. S.L. Jones Descending noradrenergic influences on pain Prog Brain Res 88 1991 381 394
27. W.D. Willis, and K.N. Westlund Neuroanatomy of the pain system and of the pathways that modulate pain J Clin Neurophysiol 14 1997 2 31